文献速递心脑血管急症重症综合管理与镇静镇痛

中重度创伤性脑损伤后升压药选择与临床及功能结局的相关性:TRACK-TBI研究

Association of Vasopressor Choice with Clinical and Functional Outcomes Following Moderate to Severe Traumatic Brain Injury: A TRACK-TBI Study.
PubMed 文献 · Neurocrit Care · 2021-08-02
一句话结论中重度TBI后48小时内初始选用去甲肾上腺素 vs 去氧肾上腺素,与6个月GOSE改善无显著相关(加权OR 1.40,95%CI 0.66-2.96,P=0.37)。

该研究为TRACK-TBI前瞻性队列(18个I级创伤中心)的回顾性分析,纳入ICU收治且入院48小时内接受静脉升压药的中重度TBI成人(GCS<13)156例。初始升压药为去甲肾上腺素79例(51%)、去氧肾上腺素69例(44%)、其他药物8例(5%)。去甲肾上腺素组6个月良好结局(GOSE 5-8)为32%,去氧肾上腺素组为40%;倾向加权回归显示去甲肾上腺素与6个月GOSE改善无显著相关(加权OR 1.40,95%CI 0.66-2.96,P=0.37),任何次要结局亦无显著差异。提示初始升压药类型的选择与临床及功能结局无显著关联,但样本量小、为回顾性分析,不能据此确立等效性或推荐某种药物。

要点

  • 适用人群为I级创伤中心收治、ICU入住且入院48小时内接受静脉升压药的中重度TBI成人(GCS<13)。
  • 初始升压药:去甲肾上腺素79例(51%)、去氧肾上腺素69例(44%)、其他8例(5%)。
  • 6个月良好结局(GOSE 5-8):去甲肾上腺素组32%,去氧肾上腺素组40%。
  • 去甲肾上腺素 vs 去氧肾上腺素与6个月GOSE无显著相关:加权OR 1.40(95%CI 0.66-2.96),P=0.37。
  • 住院时长、ICU时长、院内死亡、新需要透析、6个月DRS等次要结局均无显著差异。

适用人群与场景

  • I级创伤中心收治、入住ICU并在入院48小时内接受静脉升压药的中重度TBI成人(GCS<13)。
  • 研究纳入TRACK-TBI前瞻性队列中符合上述条件者;原文未提及其他排除标准。

诊断标准与关键阈值

  • 中重度TBI定义:Glasgow昏迷量表(GCS)评分<13。
  • 暴露定义:入院48小时内初始静脉升压药选择(去氧肾上腺素 vs 去甲肾上腺素)。
  • 主要结局:6个月Glasgow结局扩展量表(GOSE);良好结局为GOSE 5-8。

处置流程与药物剂量

  • 原文未提及具体升压药剂量、给药途径、频次、目标血压值或疗程。
  • 原文仅描述初始升压药选择为去甲肾上腺素或去氧肾上腺素,未给出用药方案细节。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:TRACK-TBI 18中心前瞻性队列的回顾性 cohort 分析;最终样本156例,男121例(77%),平均年龄43.1岁。
  • 初始升压药:去甲肾上腺素79例(51%)、去氧肾上腺素69例(44%)、其他药物8例(5%)。
  • 主要终点:去甲肾上腺素 vs 去氧肾上腺素与6个月GOSE无显著相关(加权OR 1.40,95%CI 0.66-2.96,P=0.37)。
  • 6个月良好结局(GOSE 5-8):去甲肾上腺素组32%,去氧肾上腺素组40%。
  • 次要终点(住院时长、ICU时长、院内死亡、新需要透析、6个月DRS)均无显著差异。

证据类型、等级与局限

  • 证据类型:回顾性队列研究(基于前瞻性多中心TRACK-TBI队列),采用倾向加权处理选择偏倚与患者脱落。
  • 局限:样本量小(156例)、回顾性设计、非随机分配、原文未报告证据等级或推荐强度。

对床旁实践的改变

  • 对于中重度TBI后需升压药支持血压的ICU成人,初始选择去甲肾上腺素或去氧肾上腺素与6个月功能结局无显著差异,不支持仅依据结局差异强制选择某一药物。
  • 原文未提供剂量、目标血压或疗程,不能据此制定具体用药方案;选择仍需结合个体情况。
  • 样本量小且为回顾性分析,不能据此认定两药等效,也不能推广至非I级创伤中心或未入ICU的患者。

指南或共识出处

  • 原文未提及具体指南或共识名称;仅提及当前指南建议使用静脉升压药支持TBI后血压,但未指定升压药类型。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Early hypotension following moderate to severe traumatic brain injury (TBI) is associated with increased mortality and poor long-term outcomes. Current guidelines suggest the use of intravenous vasopressors to support blood pressure following TBI; however, guidelines do not specify vasopressor type, resulting in variation in clinical practice. Minimal data are available to guide clinicians on optimal early vasopressor choice to support blood pressure following TBI. Therefore, we conducted a multicenter study to examine initial vasopressor choice for the support of blood pressure following TBI and its association with clinical and functional outcomes after injury.

METHODS: We conducted a retrospective cohort study of patients enrolled in the transforming research and clinical knowledge in traumatic brain injury (TRACK-TBI) study, an 18-center prospective cohort study of patients with TBI evaluated in participating level I trauma centers. We examined adults with moderate to severe TBI (defined as Glasgow Coma Scale score < 13) who were admitted to the intensive care unit and received an intravenous vasopressor within 48 h of admission. The primary exposure was initial vasopressor choice (phenylephrine versus norepinephrine), and the primary outcome was 6-month Glasgow Outcomes Scale Extended (GOSE), with the following secondary outcomes: length of hospital stay, length of intensive care unit stay, in-hospital mortality, new requirement for dialysis, and 6-month Disability Rating Scale. Regression analysis was used to assess differences in outcomes between patients exposed to norepinephrine versus phenylephrine, with propensity weighting to address selection bias due to the nonrandom allocation of the treatment groups and patient dropout.

RESULTS: The final study sample included 156 patients, of whom 79 (51%) received norepinephrine, 69 (44%) received phenylephrine, and 8 (5%) received an alternate drug as their initial vasopressor. 121 (77%) of patients were men, with a mean age of 43.1 years. Of patients receiving norepinephrine as their initial vasopressor, 32% had a favorable outcome (GOSE 5-8), whereas 40% of patients receiving phenylephrine as their initial vasopressor had a favorable outcome. Compared with phenylephrine, exposure to norepinephrine was not significantly associated with improved 6-month GOSE (weighted odds ratio 1.40, 95% confidence interval 0.66-2.96, p = 0.37) or any secondary outcome.

CONCLUSIONS: The majority of patients with moderate to severe TBI received either phenylephrine or norepinephrine as first-line agents for blood pressure support following brain injury. Initial choice of norepinephrine, compared with phenylephrine, was not associated with improved clinical or functional outcomes.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Toro C, Temkin N, Barber J, et al. Association of Vasopressor Choice with Clinical and Functional Outcomes Following Moderate to Severe Traumatic Brain Injury: A TRACK-TBI Study. Neurocrit Care. 2021. PMID: 34341913. doi:10.1007/s12028-021-01280-7

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。